Sanara MedTech (SMTI) FDA Approvals $24.84 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$24.84 0.00 (-0.02%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Sanara MedTech's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Sanara MedTech (SMTI). Over the past two years, Sanara MedTech has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as CellerateRX. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. CellerateRX FDA Regulatory Events CellerateRX is a drug developed by Sanara MedTech for the following indication: Surgical Powder in the Management of Spine Surgery Wounds. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - March 11,2026Publication Drug: CellerateRXAnnounced Date: March 11, 2026Indication: Surgical Powder in the Management of Spine Surgery WoundsAnnouncementSanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics.AI SummarySanara MedTech announced a peer‑reviewed study in the Journal of Medical Economics that evaluated the economic and clinical value of CellerateRX® Surgical Powder. Researchers used economic modeling to compare two groups of high‑comorbidity patients having complex spinal surgery: those who received CellerateRX as an adjunct to standard wound care and those who received standard care alone. The study tracked postoperative complications, hospital readmissions, and surgical revisions over one year. Clinical benefits were measured in quality‑adjusted life years (QALYs) and direct medical costs were expressed in 2025 U.S. dollars. The study found that adding CellerateRX led to both better health outcomes and overall cost savings versus standard care alone. Authors concluded CellerateRX can be a value‑enhancing part of the spine surgery care pathway, especially for patients who face higher risk of complications, by reducing complications, readmissions and costly revision procedures. Read Announcement Sanara MedTech FDA Events - Frequently Asked Questions Has Sanara MedTech received FDA approval? As of now, Sanara MedTech (SMTI) has not received any FDA approvals for its therapy in the last two years. What drugs has Sanara MedTech submitted to the FDA? In the past two years, Sanara MedTech (SMTI) has reported FDA regulatory activity for CellerateRX. What is the most recent FDA event for Sanara MedTech? The most recent FDA-related event for Sanara MedTech occurred on March 11, 2026, involving CellerateRX. The update was categorized as "Publication," with the company reporting: "Sanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics." What conditions do Sanara MedTech's current drugs treat? Currently, Sanara MedTech has one therapy (CellerateRX) targeting the following condition: Surgical Powder in the Management of Spine Surgery Wounds. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events HUTCHMED FDA EventsRevolution Medicines FDA EventsArtelo Biosciences FDA EventsBiogen FDA EventsNeurocrine Biosciences FDA EventsNLS Pharmaceutics FDA EventsVertex Pharmaceuticals FDA EventsAC Immune FDA EventsAptevo Therapeutics FDA EventsHeartBeam FDA EventsCandel Therapeutics FDA EventsCogent Biosciences FDA EventsDesign Therapeutics FDA EventsMoleculin Biotech FDA EventsNovoCure FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Bioventus FDA Events SS Innovations International FDA Events Spyglass Pharma FDA Events Tactile Systems Technology FDA Events Brainsway FDA Events ClearPoint Neuro FDA Events NeuroPace FDA Events Delcath Systems FDA Events Sight Sciences FDA Events Treace Medical Concepts FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:SMTI last updated on 3/11/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanara MedTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - March 11,2026Publication Drug: CellerateRXAnnounced Date: March 11, 2026Indication: Surgical Powder in the Management of Spine Surgery WoundsAnnouncementSanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics.AI SummarySanara MedTech announced a peer‑reviewed study in the Journal of Medical Economics that evaluated the economic and clinical value of CellerateRX® Surgical Powder. Researchers used economic modeling to compare two groups of high‑comorbidity patients having complex spinal surgery: those who received CellerateRX as an adjunct to standard wound care and those who received standard care alone. The study tracked postoperative complications, hospital readmissions, and surgical revisions over one year. Clinical benefits were measured in quality‑adjusted life years (QALYs) and direct medical costs were expressed in 2025 U.S. dollars. The study found that adding CellerateRX led to both better health outcomes and overall cost savings versus standard care alone. Authors concluded CellerateRX can be a value‑enhancing part of the spine surgery care pathway, especially for patients who face higher risk of complications, by reducing complications, readmissions and costly revision procedures. Read Announcement
